Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.21
-0.4%		$8.97
$2.24
▼
$12.06
$1.41B2.422.68 million shs1.97 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$29.00
+1.0%		$30.86
$17.00
▼
$35.83
$1.42B1.35408,776 shs1.13 million shs
TRAX
First Tracks Biotherapeutics
$36.44
-4.1%		$40.28
$14.72
▼
$49.91
$1.36BN/A557,747 shs619,865 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.61
$8.58
$3.55
▼
$8.61
$391.24M0.54637,200 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
-4.74%-6.36%-12.43%+21.18%+246.22%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-3.66%-7.51%-8.57%-6.02%+52.09%
TRAX
First Tracks Biotherapeutics
-4.02%-10.66%-18.76%+115.31%+3,797,999,900.00%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%0.00%0.00%0.00%+0.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Absci Corporation stock logo
ABSI
Absci
$8.21
-0.4%		$8.97
$2.24
▼
$12.06
$1.41B2.422.68 million shs1.97 million shs
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
$29.00
+1.0%		$30.86
$17.00
▼
$35.83
$1.42B1.35408,776 shs1.13 million shs
TRAX
First Tracks Biotherapeutics
$36.44
-4.1%		$40.28
$14.72
▼
$49.91
$1.36BN/A557,747 shs619,865 shs
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$8.61
$8.58
$3.55
▼
$8.61
$391.24M0.54637,200 shsN/A
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Absci Corporation stock logo
ABSI
Absci
-4.74%-6.36%-12.43%+21.18%+246.22%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-3.66%-7.51%-8.57%-6.02%+52.09%
TRAX
First Tracks Biotherapeutics
-4.02%-10.66%-18.76%+115.31%+3,797,999,900.00%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%0.00%0.00%0.00%+0.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Absci Corporation stock logo
ABSI
Absci
2.80
Moderate Buy$13.7167.04% Upside
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
2.70
Moderate Buy$44.8654.68% Upside
TRAX
First Tracks Biotherapeutics
2.73
Moderate Buy$63.0072.89% Upside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest YMAB, ABSI, TRAX, and AVBP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Absci Corporation stock logo
ABSI
Absci
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
9/8/2026
Absci Corporation stock logo
ABSI
Absci
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetBuy$15.00
9/8/2026
Absci Corporation stock logo
ABSI
Absci
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$13.00 ➝ $16.00
9/3/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$57.00
8/18/2026
TRAX
First Tracks Biotherapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$83.00
8/17/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $47.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell (D)
8/13/2026
TRAX
First Tracks Biotherapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$54.00 ➝ $95.00
8/13/2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$43.00 ➝ $40.00
8/13/2026
TRAX
First Tracks Biotherapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$44.00 ➝ $57.00
8/13/2026
TRAX
First Tracks Biotherapeutics
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$48.00 ➝ $65.00
(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Absci Corporation stock logo
ABSI
Absci
$2.80M503.19N/AN/A$1.26 per share6.52
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/A$7.44 per shareN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M4.46N/AN/A$2.05 per share4.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Absci Corporation stock logo
ABSI
Absci
-$115.18M-$0.80N/AN/AN/A-7,756.38%-61.71%-54.52%11/16/2026 (Estimated)
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$166.31M-$3.62N/AN/AN/AN/A-50.26%-46.66%11/16/2026 (Estimated)
TRAX
First Tracks Biotherapeutics
N/A-$1.84N/AN/AN/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.50N/AN/AN/A-26.03%-24.60%-18.89%N/A

Latest YMAB, ABSI, TRAX, and AVBP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
-$0.9873-$1.05-$0.0627-$1.05N/AN/A
8/12/2026Q2 2026
TRAX
First Tracks Biotherapeutics
-$0.74-$0.95-$0.21-$0.95N/AN/A
8/11/2026Q2 2026
Absci Corporation stock logo
ABSI
Absci
-$0.1910-$0.21-$0.0190-$0.21$0.92 million$0.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Absci Corporation stock logo
ABSI
Absci
N/AN/AN/AN/AN/A
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/AN/AN/AN/AN/A
TRAX
First Tracks Biotherapeutics
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Absci Corporation stock logo
ABSI
Absci
N/A
10.63
10.63
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
N/A
14.16
14.16
TRAX
First Tracks Biotherapeutics
N/A
14.28
14.28
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.00
3.58

Institutional Ownership

CompanyInstitutional Ownership
Absci Corporation stock logo
ABSI
Absci
52.05%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
9.48%
TRAX
First Tracks Biotherapeutics
N/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%

Insider Ownership

CompanyInsider Ownership
Absci Corporation stock logo
ABSI
Absci
10.52%
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
8.58%
TRAX
First Tracks Biotherapeutics
N/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Absci Corporation stock logo
ABSI
Absci
210171.61 million153.56 millionOptionable
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
4049.31 million45.08 millionN/A
TRAX
First Tracks Biotherapeutics
N/A35.73 millionN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.44 million36.49 millionOptionable

Recent News About These Companies

Y-Mabs Therapeutics Completes Merger with Perseus BidCo
September 16, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/y-mabs-therapeutics-completes-merger-with-perseus-bidco?utm_source=marketbeat.com&utm_medium=referral
Y-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma Treatment
September 7, 2025  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/y-mabs-therapeutics-phase-2-trial-a-potential-breakthrough-for-neuroblastoma-treatment/ar-AA1M46dw
Y-mAbs Therapeutics, Inc. (YMAB) Now Trades Above Golden Cross: Time to Buy?
September 1, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2745527/y-mabs-therapeutics-inc-ymab-now-trades-above-golden-cross-time-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|golden_crossover-2745527
Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
August 19, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/20/3136088/6713/en/y-mabs-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-y-mabs-therapeutic.html
Acquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics Stock
August 13, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/acquisition-deal-triggers-weekly-surge-for-y-mabs-therapeutics-stock-1589285/
A Look Ahead: Y-mAbs Therapeutics's Earnings Forecast
August 9, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/08/46970486/a-look-ahead-y-mabs-therapeuticss-earnings-forecast
Y-mAbs (YMAB) Q2 Revenue Falls 14%
August 9, 2025  |  aol.comA
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
August 8, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2683340/y-mabs-therapeutics-inc-ymab-reports-q2-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2683340
Shareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public Shareholders
August 8, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250808933548/en/shareholder-alert-the-ademi-firm-investigates-whether-y-mabs-therapeutics-inc.-is-obtaining-a-fair-price-for-its-public-shareholders/
Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments
August 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/08/3130042/0/en/y-mabs-reports-second-quarter-2025-financial-results-and-recent-corporate-developments.html
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
August 7, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-y-mabs-therapeutics-inc-nasdaq-ymab-302524869.html
Y-MABS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
August 7, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250807034703/en/y-mabs-therapeutics-investor-alert-by-the-former-attorney-general-of-louisiana-kahn-swick-foti-llc-investigates-adequacy-of-price-and-process-in-proposed-sale-of-y-mabs-therapeutics-inc.---ymab/
Y-mAbs Therapeutics, Inc. to Report Q2 2025 Financial Results on August 8, 2025, forgoing Earnings Call
August 7, 2025  |  quiverquant.comQ
Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025
August 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/07/3129120/0/en/y-mabs-to-announce-second-quarter-2025-financial-and-operating-results-on-august-8-2025.html
HC Wainwright & Co. Downgrades Y-mAbs Therapeutics (YMAB)
August 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/hc-wainwright-co-downgrades-y-mabs-therapeutics-ymab/ar-AA1K3Nlv
SERB bets on rare cancer drug in $412 million deal for Y-mAbs
August 6, 2025  |  thepharmaletter.comT
Jones Trading Downgrades Y-mAbs Therapeutics (YMAB)
August 6, 2025  |  msn.comhttps://www.msn.com/en-us/money/markets/jones-trading-downgrades-y-mabs-therapeutics-ymab/ar-AA1K27jE
YmAbs Therapeutics (YMAB) Surges 103.3%: Is This an Indication of Further Gains?
August 6, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2673237/ymabs-therapeutics-ymab-surges-103-3-is-this-an-indication-of-further-gains?cid=cs-stocknewsapi-ft-tale_of_the_tape|daily_price_change_5%-2673237
Shareholder Alert: The Ademi Firm investigates whether Y-mAbs Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
August 5, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-y-mabs-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302522065.html
Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition
August 5, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/ymabs-stock-soars-after-serb-pharmaceuticals-announces-acquisition-93CH-4170530

New MarketBeat Followers Over Time

Media Sentiment Over Time

Absci stock logo

Absci NASDAQ:ABSI

$8.21 -0.03 (-0.36%)
Closing price 04:00 PM Eastern
Extended Trading
$8.25 +0.04 (+0.48%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

ArriVent BioPharma stock logo

ArriVent BioPharma NASDAQ:AVBP

$29.00 +0.30 (+1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$29.02 +0.02 (+0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

First Tracks Biotherapeutics NASDAQ:TRAX

$36.44 -1.54 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$36.40 -0.04 (-0.12%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas